Technical Data
BAFF (B cell Activating Factor belonging to TNF Family, BLyS, TALL-1, THANK)
Members in the TNF superfamily regulate immune responses and induce apoptosis. A novel member in the TNF family was recently identified by several groups and designated BAFF, BLyS, TALL-1, THANK, and zTNF4. BAFF/BLyS was characterized as a B cell activator since it induced B cell proliferation and immunoglobulin secretion. Two receptors, TACI and BCMA, for BAFF were originally identified. A third receptor was identified recently and designated BAFF-R and BR3 for BLyS receptor 3. Unlike BCMA and TACI, which bind to BAFF and April, BAFF-R/BR3 is specific for BAFF and plays a predominant role in BAFF induced B cell development and survival. BAFF and its receptors are involved in B cell associated autoimmune diseases, and activate NF-eB and c-jun N-terminal kinase.

Suitable for use in Flow Cytometry, Western Blot and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: Frozen and Paraffin.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile 40-50% glycerol, aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
MabIgM6D7Highly Purified
100ug4C (-20C Glycerol)Blue IceHumanRat
Recombinant human soluble BAFF (aa 83-285).
Highly purified (SDS-PAGE).
Supplied as a liquid in PBS, 0.02% sodium azide.
Recognizes membrane-bound and soluble human and mouse (weak) BAFF.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. J. Groom, et al.; J. Clin. Invest. 109: 59 (2002). 2. A. J. Novak, et al.; Blood 103: 689 (2004). 3. B. He, et al.; J. Immunol. 172: 3268 (2004). 4. Int. Immunol. 16: 467 (2004). 5. A.J. Novak, et al.; Blood 104: 2247 (2004). 6. M.V. Jonsson, et al.; J. Clin. Immunol. 25: 189 (2005). 7. F. Mackay, et al.; J. Exp. Med. 190: 1697 (1999) 8.P.A. Moore, et al.; Science 285: 260 (1999). 9.A. Mukhopadhyay, et al.; J. Biol. Chem. 274: 15978 (1999). 10. P. Schneider, et al.; J. Exp. Med. 189: 1747 (1999). 11.H.B. Shu, et al.; J. Leukoc. Biol. 65: 680 (1999).12.S.D. Khare, et al.; PNAS 97: 3370 (2000).